Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer
NCT04052412 is a phase 1 interventional trial sponsored by University of Tennessee. As of 21 Nov 2026, it has a status the registry marks as unknown. It studies 18F-AraG in Non-small Cell Lung Cancer. The registry lists an enrollment of 2 participants at 1 site in 1 country. The registry lists a start date of 16 Jul 2019 and a primary completion date of 31 Dec 2023.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04052412 |
| Status | Unknown |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | University of Tennessee |
| Enrollment | 2 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Non-small Cell Lung Cancer |
| Drugs | 18F-AraG |
| Start | 16 Jul 2019 |
| Primary completion | 31 Dec 2023 |
| Study completion | 31 Dec 2023 |
| Last update posted | 13 May 2022 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Dustin Osborne, PhD
University of Tennessee
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Tennessee Medical Center
Knoxville
Dustin Osborne, PhDFrancis J Turner, MDJacob Noe, MDJoseph Kelley, MDYitong Fu, MDRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04052412
Each answer restates registry values shown on this page.
What is NCT04052412?
NCT04052412 is a phase 1 interventional trial sponsored by University of Tennessee. It studies 18F-AraG in Non-small Cell Lung Cancer.
Who leads NCT04052412?
The registry names Dustin Osborne, PhD (principal investigator, University of Tennessee) as the overall official.
Where does NCT04052412 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04052412 study?
The registered drug and biological interventions are 18F-AraG.
When is NCT04052412 expected to complete?
The registry lists a primary completion date of 31 Dec 2023 and a study completion date of 31 Dec 2023. The sponsor last updated the record on 13 May 2022.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.